Risk of Major Adverse Cardiovascular Events in Patients Treated with Febuxostat Compared to Allopurinol: A Systematic Review and Meta-Analysis
{{output}}
Introduction: To evaluate the cardiovascular safety of febuxostat compared to allopurinol in patients with gout or hyperuricemia, with a focus on Major Adverse Cardiovascular Event (MACE) outcomes. ... ...
